Vilon
Vilon reaches for the same broad target as Thymosin Alpha-1 — immune function in aging — through an entirely different, and more speculative, route: it's the shortest peptide in the Khavinson bioregulator family.
Not currently stocked by KYIN Peptides, but available to order — see availability below.
What Is Vilon?
Vilon is the shortest peptide in the Khavinson bioregulator family — a two-amino-acid dipeptide (Lys-Glu) — proposed to bind DNA in thymic tissue and influence gene expression governing T-cell maturation. Like other bioregulator peptides in this lineage, it works by a proposed direct chromatin-binding mechanism rather than a conventional cell-surface receptor pathway. It was distilled from Thymalin, the original calf-thymus polypeptide extract from the same research program, as a minimal single-molecule fragment intended to capture Thymalin's proposed active core.
Research Focus
Vilon is relevant to general immune function and health in aging rather than localized tissue repair, distinguishing it from the gastric-, actin-, and copper-based repair pathways studied for compounds like BPC-157 and TB-500. It shares its broad research target — immune modulation — with Thymosin Alpha-1, though the two compounds reach for it through very different mechanisms and very different levels of evidence — see the full Thymosin Alpha-1 vs Vilon comparison. See our Healing & Recovery research overview for how it fits alongside KYIN's stocked recovery-focused peptides, or our Khavinson bioregulator peptides overview for the full family.
Clinical & Preclinical Trial Data
The core evidence for Vilon is a single, decades-old animal lifespan study (Khavinson & Anisimov, Doklady Biological Sciences): chronic Vilon administration in female CBA mice — a strain predisposed to spontaneous mammary tumors — extended lifespan by 20–40% and reduced the incidence of spontaneous lung adenomas, without significantly changing body weight or food consumption. This has not been independently replicated outside Khavinson-affiliated Russian research, and no human trial of Vilon has been conducted.
Availability
Vilon is not part of KYIN Peptides' standard catalogue, but it is available to order — contact us directly and we'll source it for you.
Vilon questions
What is Vilon?
Vilon is the shortest peptide in the Khavinson bioregulator family — a two-amino-acid dipeptide (Lys-Glu) — proposed to bind DNA in thymic tissue and influence gene expression governing T-cell maturation, targeting immune function in aging.
What evidence exists for Vilon?
The core evidence is a single, decades-old animal lifespan study (Khavinson & Anisimov): chronic Vilon administration in female CBA mice extended lifespan by 20–40% and reduced the incidence of spontaneous lung adenomas. This has not been independently replicated outside Khavinson-affiliated Russian research, and no human trial of Vilon has been conducted.
How does Vilon compare to Thymosin Alpha-1?
Both are immune-modulation compounds outside KYIN's tissue-repair peptides, but their evidence bases are worlds apart. Vilon's evidence is a single, unreplicated 1990s animal study; Thymosin Alpha-1 has large modern trials behind it and is an approved drug in 35+ countries. See the full Thymosin Alpha-1 vs Vilon comparison.
Does KYIN Peptides sell Vilon?
Not as part of our standard catalogue, but yes — it's available to order. Contact us directly and we'll source it for you.
Interested in sourcing Vilon?
Contact us and we'll help you source it, or browse our stocked recovery-focused peptides.